Cellomics and BD Sign License Agreement to Further Expand Availability of High Content Screening
11-Nov-2004 -
Cellomics, Inc., the creator of High Content Screening (HCS), and global medical technology company BD (Becton, Dickinson and Company), through its BD Biosciences unit, announced that they have entered into a non-exclusive, worldwide patent license agreement. The agreement will provide BD with ...
business development
flow cytometry
license agreements
+1